Abstract
Introduction COVID-19 pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of immense global public health concern. RP7214, a novel, potent, oral, inhibitor of DHODH, has shown preclinical evidence in inhibiting viral replication and lung inflammation.
Methods This was a randomized, double-blind, placebo-controlled phase 2 study in patients with symptomatic mild SARS-CoV-2 infection, having at least one high-risk feature (e.g., hypertension, diabetes mellitus) for developing severe Covid-19 infection. The patients received RP7214 (400 mg BID) or a placebo for 14 days in a blinded fashion and were followed up to 30 days. Patients also received supportive therapy (e.g., antipyretics and antitussives for symptomatic relief) at the discretion of the investigator. The endpoints were Covid 19 related hospitalization rate by Day 15, SARS-CoV-2 viral load and clearance on Days 3,7 and 15, clinical symptoms improvement by Day 15, safety, and the immuno-modulatory effect of RP7214.
Results A total of 163 patients were treated in the study; 82 received RP7214 and 81 received placebo. Of the total patients, 44.2% had received Covid-19 vaccine prior to the study. The symptom onset was ≤ 3 days in 22.1%. None of the patients in the study required hospitalization. There was no difference in the mean change of viral load between RP7214 and placebo. In the subgroup analysis, in patients having symptom onset of ≤ 3 days, RP7214 significantly reduced viral load on Days 3 and 7, respectively. Similarly, in non-vaccinated patients with symptom onset of ≤ 3 days, RP7214 significantly reduced viral load on Day 3. Overall, there was a trend towards better viral load reduction in RP7214-treated patients with a baseline viral load of 5 log units or higher. For all other endpoints, there was no difference between RP7214 and placebo. Majority of the reported AEs were mild and not related either to study treatment.
Conclusions RP7214 at 400 mg BID dose level showed a statistically significant reduction in viral load at an early stage of the disease and in non-vaccinated patients. There was a trend towards better viral load reduction in RP7214-treated patients with a baseline viral load of 5 log units or higher. RP7214 showed a favorable safety profile. Further development of RP7214 in Covid 19 in a mild symptomatic population with co-morbidities and treated at an early stage of disease may show benefit.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05007236
Funding Statement
This work was supported by Incozen Therapeutics Pvt Ltd., Lab Suites 231-234, Building 450, MN Science and Technology Park, Genome Valley, Turkapally (V), Shameerpet Mandal, Hyderabad-500078, Telangana, India
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Human Ethics Committee of Panimalar Medical college hospital and research Institute, Chennai, India gave the first ethics approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declaration of Conflicting Interests Prajak Barde, Kasi V Routhu, and Ajit Nair are employed at Rhizen Pharmaceuticals. Swaroop V. Vakkalanka has equity, ownership & employment at Incozen therapeutics Pvt Ltd. All authors retained full ownership of the manuscript content and approved the final draft for submission
Data Availability Statement The data that support the findings of this study are available from the corresponding author Ajit Nair upon reasonable request.
Funding This work was supported by Incozen Therapeutics Pvt Ltd., Lab Suites 231-234, Building 450, MN Science and Technology Park, Genome Valley, Turkapally (V), Shameerpet Mandal, Hyderabad-500078, Telangana, India
Ethics Approval Statement The study was approved by the Drug Controller General of India (DCGI) (New Delhi, India) and the Institutional Ethics Committee(s) (IEC). The study complies with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines and the current revision of the Declaration of Helsinki. In addition, the study was conducted in compliance with local regulatory and ethical requirements, ‘Indian GCP guidelines’ ‘New Drugs and Clinical Trials Rules 2019’ and ‘Ethical Guidelines for Biomedical Research on Human Subjects’ issued by the Indian Council of Medical Research in 2017.
The protocol, informed consent form(s), and all patient materials were approved by all Institutional/Independent Ethics Committee (EC). All the Ethics Committee’s were approved committees by the DCGI as per New Drugs and Clinical Trial Rules 2019.
Patient Consent Statement All subjects provided written informed consent prior to enrollment.
Permission to Reproduce Material from Other Sources Not applicable.
Data Availability
The data that support the findings of this study are available from the corresponding author Ajit Nair upon reasonable request.
